Short Interest in Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Rises By 27.7%

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 2,310,700 shares, an increase of 27.7% from the March 15th total of 1,808,800 shares. Based on an average trading volume of 300 shares, the short-interest ratio is presently 7,702.3 days.

Neuren Pharmaceuticals Stock Performance

OTCMKTS NURPF traded down C$0.29 on Friday, reaching C$7.34. The stock had a trading volume of 6,100 shares, compared to its average volume of 1,113. Neuren Pharmaceuticals has a 1 year low of C$6.61 and a 1 year high of C$14.25. The business has a 50 day moving average price of C$7.70 and a 200 day moving average price of C$8.04.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.